Profile data is unavailable for this security.
About the company
Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
- Revenue in EUR (TTM)527.00k
- Net income in EUR-8.94m
- Incorporated2014
- Employees52.00
- LocationValbiotis SA12F rue Paul VatinePERIGNY 17180FranceFRA
- Phone+33 546286258
- Fax+33 546286258
- Websitehttps://www.valbiotis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theranexus SA | 0.00 | -3.08m | 3.94m | 12.00 | -- | -- | -- | -- | -0.3971 | -0.3971 | 0.00 | -0.0004 | 0.00 | -- | -- | 0.00 | -50.35 | -42.66 | -64.95 | -47.97 | -- | -- | -- | -- | -- | -420.89 | 1.00 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
| Quantum Genomics SA | 0.00 | -9.40m | 5.03m | 3.00 | -- | -- | -- | -- | -0.1519 | -0.1519 | 0.00 | -0.0255 | 0.00 | -- | -- | 0.00 | -282.86 | -60.77 | -422.81 | -102.24 | -- | -3,548.91 | -- | -3,374.13 | -- | -131.78 | 3.97 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Acticor Biotech SA | 0.00 | -15.86m | 5.36m | 28.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.4011 | 0.00 | -- | -- | 0.00 | -129.36 | -- | -695.94 | -- | -- | -- | -- | -- | -- | -- | 3.71 | -- | -- | -- | -17.40 | -- | -- | -- |
| Predilife SA | 317.79k | -4.22m | 14.20m | 19.00 | -- | -- | -- | 44.69 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Poxel SA | 1.98m | -35.09m | 14.25m | 22.00 | -- | -- | -- | 7.19 | -1.08 | -1.08 | 0.0591 | -1.27 | 0.1002 | -- | 5.09 | 90,045.45 | -177.50 | -52.39 | -- | -92.20 | 0.0505 | -- | -1,771.33 | -299.15 | -- | -1.39 | -- | -- | 193.92 | -49.84 | -11.76 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 1.68m | 79.16k | 14.37m | 27.00 | 178.05 | 1.67 | 24.78 | 8.54 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | 62,278.52 | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Phaxiam Therapeutics SA | 2.14m | -21.92m | 17.92m | 54.00 | -- | 0.7038 | -- | 8.37 | -3.46 | -3.46 | 0.3956 | 2.54 | 0.0409 | -- | 8.56 | 41,980.39 | -41.90 | -50.69 | -61.11 | -66.25 | -- | -- | -1,023.96 | -1,009.09 | -- | -70.91 | 0.4556 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Valbiotis SA | 527.00k | -8.94m | 18.70m | 52.00 | -- | 1.11 | -- | 35.49 | -0.6571 | -0.6571 | 0.0373 | 1.07 | 0.0208 | 2.52 | 0.2447 | 10,134.62 | -35.21 | -32.92 | -46.61 | -46.36 | -511.95 | 53.15 | -1,697.15 | -418.87 | 4.54 | -91.62 | 0.266 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Oncodesign Precision Medicine Opm SA | 468.73k | -7.78m | 19.28m | 19.00 | -- | 6.12 | -- | 41.14 | -0.449 | -0.449 | 0.0269 | 0.1733 | 0.0311 | -- | 0.4553 | 21,305.91 | -51.68 | -- | -85.27 | -- | 153.18 | -- | -1,660.23 | -- | -- | -360.87 | 0.715 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Nfl Biosciences SAS | 0.00 | -2.37m | 20.28m | 4.00 | -- | 5.83 | -- | -- | -0.2653 | -0.2653 | 0.00 | 0.3584 | 0.00 | -- | -- | 0.00 | -44.70 | -83.27 | -70.88 | -122.37 | -- | -- | -- | -- | -- | -- | 0.0151 | -- | -- | -- | -53.28 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Valbiotis SA's reporting currency: Euro EUR
8.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| OFI Invest Asset Management SAas of 29 Aug 2024 | 719.62k | 4.56% |
| Talence Gestion SASas of 30 Aug 2024 | 256.39k | 1.62% |
| UBS LA MAISON de Gestionas of 30 Dec 2022 | 150.00k | 0.95% |
| Hermitage Gestion Priv�e SAas of 29 Dec 2023 | 80.00k | 0.51% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 79.99k | 0.51% |
| Pure Capital SAas of 31 Dec 2023 | 44.84k | 0.28% |
| MW Gestion SAas of 31 Dec 2023 | 33.63k | 0.21% |
| Amiral Gestion SAas of 29 Dec 2023 | 18.84k | 0.12% |
| Mandarine Gestion SAas of 28 Jun 2024 | 16.24k | 0.10% |
| Gestys SAas of 30 Aug 2024 | 12.50k | 0.08% |
More ▼
Data from 29 Dec 2023 - 30 Oct 2024Source: FactSet Research Systems Inc.
